AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.050

+0.0024.17%

Volume:420.79K

Turnover:20.03K

Market Cap:60.44M

PE:-8.62

High:0.050

Open:0.047

Low:0.046

Close:0.048

52wk High:0.125

52wk Low:0.046

Shares:1.21B

Float Shares:895.86M

Volume Ratio:0.53

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.006

EPS(LYR):-0.006

ROE:-40.41%

ROA:-26.35%

PB:4.27

PE(LYR):-8.62

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

THOMSON REUTERS

Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101

THOMSON REUTERS

Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/ALA.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.05,"timestamp":1790823165853,"preClose":0.048,"halted":0,"volume":420793,"delay":0,"changeRate":0.041666666666666706,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1208783672,"eps":-0.0058,"marketStatus":"Trading","change":0.002,"latestTime":"10-01 12:54:47 AEST","open":0.047,"high":0.05,"low":0.046,"amount":20030,"amplitude":0.083333,"askPrice":0.05,"askSize":169558,"bidPrice":0.048,"bidSize":44104,"shortable":3,"etf":0,"ttmEps":-0.0058,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.048,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":0.528628,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.048,"auctionPrice":0.048,"auctionVolume":20000,"auction":3,"marketStatus":"盘后竞价","timestamp":1790748594939}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-26.35%","roe":"-40.41%","lyrEps":-0.0058,"volumeRatio":0.528628,"shares":1208783672,"dividePrice":0,"high":0.05,"amplitude":0.083333,"preClose":0.048,"low":0.046,"week52Low":0.046,"pbRate":"4.27","psRate":"17.28","week52High":0.125,"institutionHeld":0,"latestPrice":0.05,"committee":-0.587161,"eps":-0.0058,"divideRate":0,"volume":420793,"delay":0,"ttmEps":-0.0058,"open":0.047,"prevYearClose":0.093,"prevWeekClose":0.054,"prevMonthClose":0.048,"prevQuarterClose":0.048,"fiveDayClose":0.053,"twentyDayClose":0.06,"sixtyDayClose":0.066},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651119902","title":"Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119902?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRL","LU0757428866.USD","BK4585","IE00BFMHRM44.USD","BK4530","LU1815336091.USD","BK7096","LU0029874061.USD","LU0128526141.USD","BK4588","LU0390134368.USD","ALA.AU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119191","title":"Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119191?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0029874061.USD","LU1815336091.USD","BK4585","ALA.AU","BK7096","LU0757428866.USD","CRL","LU0390134368.USD","BK4121","LU0128526141.USD","BK4530","BK4588","IE00BFMHRM44.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651211993","title":"Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2651211993","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651211993?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:01","pubTimestamp":1783944066,"startTime":"0","endTime":"0","summary":"Charles River to provide GMP NGS testing services to Arovella Therapeutics under new collaborationCharles River entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL4DdDks:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","LU0757428866.USD","BK4585","IE00BFMHRM44.USD","BK4530","LU1815336091.USD","BK7096","LU0029874061.USD","LU0128526141.USD","BK4588","LU0390134368.USD","ALA.AU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646825419","title":"Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2646825419","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646825419?lang=en_us&edition=fundamental","pubTime":"2026-06-25 11:31","pubTimestamp":1782358272,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T  cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALA.AU","LENZ","BK4139","BK4539","BK4007","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALA.AU\",params:#limit:6,delay:true,,,undefined,":[]}}